Drug Profile
Glutazumab - Gmax Biopharm
Alternative Names: GMA-102Latest Information Update: 02 Jan 2023
Price :
$50
*
At a glance
- Originator Gmax Biopharm
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Type 2 diabetes mellitus
Most Recent Events
- 02 Jan 2023 Phase-III development is ongoing in China
- 20 Jan 2021 Glutazumab - Gmax Biopharm is available for licensing for phase III development in World (excluding China) as of 20 Jan 2021. http://www.gmaxbiopharm.com/pipeline/id/7.html
- 20 Jan 2021 Phase-III clinical trials in Type 2 diabetes mellitus in China (SC) (Gmax Biopharm pipeline, January 2021)